Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

Sound Shore Management, an investment management firm, has released its investor letter for the first quarter of 2025. A copy ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® ...

Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva ...

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International ...